
Chemours (CC) faces a complex environment with a 59% stock decline over the past year and a volatile beta of 1.74, though Q3 2024 EBITDA beat estimates at $208 million; however, analysts have revised earnings expectations downward, and the company cut its dividend by 65% to fund growth initiatives like OPTEON and data center cooling technologies. The company is targeting $250 million in cost savings, and analysts see long-term potential in environmentally friendly cooling solutions and the data center market, balanced against PFAS liabilities and regulatory uncertainties.
The Chemours Company (CC) is navigating a complex operating environment, reflected in a 59% stock price decline over the past year and a volatile beta of 1.74, despite reporting Q3 2024 EBITDA of $208 million, which surpassed analyst estimates. However, this is contrasted by underlying challenges: the company's trailing twelve-month EBITDA is $715 million, while it faces rapid cash consumption (negative free cash flow yield of -52%), a significant debt burden (debt-to-equity ratio of 7.57), and a "FAIR" financial health score of 1.76 from InvestingPro. Seven analysts have revised earnings expectations downward, and Chemours' Q4 guidance implied an EBITDA of $166 million, below consensus. Strategically, Chemours cut its dividend by 65% to fund growth in Opteon refrigerants and data center cooling, alongside targeting $250 million in cost savings ($125 million run-rate by end-2025). The Thermal & Specialized Solutions and Advanced Performance Materials segments are key growth drivers, particularly with Opteon benefiting from regulatory shifts and a $3 billion TAM for data center cooling. Conversely, the Titanium Technologies segment faces headwinds. Persistent PFAS liabilities and macroeconomic uncertainties remain significant risks, tempering the FY2025 EBITDA guidance of $825-$975 million.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment